A Prospective, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety of a New 6:2 Influenza Virus Reassortant in Healthy Adults
18 Years - 49 Years
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Prevention
Verified 01 Jul 2011 by MedImmune, LLC
No locations available
|Experimental: Monovalent influenza virus vaccine|
Frozen monovalent vaccine containing new strain
Biological/Vaccine: Monovalent influenza virus vaccine
Monovalent vaccine was supplied in intranasal sprayers containing a total volume of 0.5 mL of sucrose-phosphate buffer, egg allantoic fluid, and approximately 10^7 FFU (fluorescent focus units) of the cold-adapted, attenuated, 6:2 reassortant influenza strain B/Brisbane/60/2008 (Victoria lineage).
|Placebo Comparator: Placebo|
Placebo was supplied in intranasal sprayers containing 0.5 mL of sucrose-phosphate buffer.